![]() |
|
|
Vol. 55, Issue 2, 202-209, February 1999
Department of Psychiatry, New York University Medical Center, New
York, New York (J.Y.L., A.G.-E., K.Y.L., K.D.C., M.G., E.M.);
and
Department of Biochemistry and Molecular Biology, Louisiana State
University Medical Center, New Orleans, Louisiana (J.W.H.)
Activation of striatal dopamine (DA) neurons by neuroleptic treatment
or by electrical stimulation of the nigrostriatal pathway increases the
activity of tyrosine hydroxylase (TH). The increase is mediated by
phosphorylation of the enzyme. However, abolition of DA neuronal
activity [by
-butyrolactone (GBL) treatment or transection of the
nigrostriatal pathway] also increases TH activity. Quantitative blot
immunolabeling experiments using site- and phosphorylation state-specific antibodies to TH demonstrated that GBL treatment (750 mg/kg, 35 min) significantly increased phosphorylation at Ser19 (+40%)
and Ser40 (+217%) without altering Ser31 phosphorylation. Concomitantly, GBL treatment [along with the
3,4-dihydroxyphenylalanine (dopa) decarboxylase inhibitor
NSD-1015, 100 mg/kg, 30 min] increased in vivo striatal dopa
accumulation and in vitro TH activity 3-fold. Likewise, cerebral
hemitransection of the nigrostriatal pathway significantly increased
phosphorylation of TH at Ser19 (+89%) and Ser40 (+158%) but not at
Ser31; dopa levels were increased accordingly (+191%). Kinetic
analysis of TH activity established that GBL treatment and
hemitransection primarily decreased the Km
for the cofactor tetrahydrobiopterin (3-fold). The effects of GBL and
hemitransection were abolished or attenuated by pretreatment with the
DA agonist
R-(
)-N-n-propylnorapomorphine
(NPA; 30 µg/kg, 40 min), presumably via stimulation of inhibitory
presynaptic DA autoreceptors. NPA dose-response curves for reversal of
GBL-induced dopa accumulation and Ser40 phosphorylation were identical;
however, only the highest dose of NPA reversed the small and variable
increase in Ser19 phosphorylation. Thus, TH activity seems to be
regulated by phosphorylation in both hyper- and hypoactive striatal DA
neurons; in the latter case, activation seems to be caused by selective phosphorylation of Ser40.
This article has been cited by other articles:
![]() |
A. Saraf, D. M. Virshup, and S. Strack Differential Expression of the B'beta Regulatory Subunit of Protein Phosphatase 2A Modulates Tyrosine Hydroxylase Phosphorylation and Catecholamine Synthesis J. Biol. Chem., January 5, 2007; 282(1): 573 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Schulz, S. A. Noggle, G. M. Palmarini, D. A. Weiler, I. G. Lyons, K. A. Pensa, A. C.B. Meedeniya, B. P. Davidson, N. A. Lambert, and B. G. Condie Differentiation of Human Embryonic Stem Cells to Dopaminergic Neurons in Serum-Free Suspension Culture Stem Cells, December 1, 2004; 22(7): 1218 - 1238. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kobori, J. C. Waymire, J. W. Haycock, G. L. Clifton, and P. K. Dash Enhancement of Tyrosine Hydroxylase Phosphorylation and Activity by Glial Cell Line-derived Neurotrophic Factor J. Biol. Chem., January 16, 2004; 279(3): 2182 - 2191. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Kumar, D.-K. Kim, M.-S. Lee, R. Ramachandran, and N. R. Prabhakar Activation of tyrosine hydroxylase by intermittent hypoxia: involvement of serine phosphorylation J Appl Physiol, August 1, 2003; 95(2): 536 - 544. [Abstract] [Full Text] [PDF] |
||||